Fintel reports that on November 18, 2025, Evercore ISI Group initiated coverage of Upstream Bio (NasdaqGS:UPB) with a Outperform recommendation.
Analyst Price Forecast Suggests 142.10% Upside
As of November 17, 2025, the average one-year price target for Upstream Bio is $62.22/share. The forecasts range from a low of $47.47 to a high of $78.75. The average price target represents an increase of 142.10% from its latest reported closing price of $25.70 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.40.
What is the Fund Sentiment?
There are 215 funds or institutions reporting positions in Upstream Bio. This is an increase of 26 owner(s) or 13.76% in the last quarter. Average portfolio weight of all funds dedicated to UPB is 0.29%, an increase of 13.61%. Total shares owned by institutions decreased in the last three months by 6.50% to 46,831K shares. 
The put/call ratio of UPB is 0.04, indicating a bullish outlook.
What are Other Shareholders Doing?
Orbimed Advisors holds 5,694K shares representing 10.54% ownership of the company. No change in the last quarter.
Decheng Capital holds 3,285K shares representing 6.08% ownership of the company. No change in the last quarter.
Enavate Sciences GP holds 2,460K shares representing 4.55% ownership of the company. No change in the last quarter.
Bain Capital Life Sciences Investors holds 2,440K shares representing 4.51% ownership of the company. No change in the last quarter.
TCG Crossover Management holds 2,117K shares representing 3.92% ownership of the company. In its prior filing, the firm reported owning 2,802K shares , representing a decrease of 32.34%. The firm decreased its portfolio allocation in UPB by 44.25% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
